Global medical device company Olympus has announced that U.S Food and Drug Administration (FDA) has cleared its CELERIS single-use sinus debrider system.

The CELERIS system is indicated for cutting, coagulation, debriding and removal of thin bone and soft tissue in general ENT and sinus/rhinology procedures.

The system’s tiny and portable design allows it to do less invasive treatments in almost any treatment room.

The CELERIS is also designed to eliminate the expenditures of reprocessing and maintenance that comes associated with a full debrider system.

It comes with a standard 4mm device and 2mm and 4mm devices with the bipolar capability to manage incidental bleeding avoiding the need to change instruments.

By providing a bendability up to 60 degrees, the 4mm device enables a physician to access more places without any need to switch devices mid-procedure. The system allow easy installation and plugs into standard wall outlet.

Olympus Americas ENT business unit leader and vice president Dana Currier said: “While a full debrider system may be the right device in certain cases, the single-use CELERIS debrider offers physicians another option for most of their routine procedures,”

“Its simple setup and single-use design allows physicians to treat patients in the more comfortable setting of an office treatment room rather than an OR.  And it can help improve patient outcomes by offering a bipolar energy option to manage incidental bleeding.”

In March last year, Olympus received the FDA 510(k) clearance for its Narrow Band Imaging (NBI) to evaluate the neoplastic potential of colorectal polyps.